Macrocyclic Chelators for Selective Thorium Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chelating agents for anticancer therapy lack selectivity towards thorium, leading to depletion of essential biological metal ions, causing health issues, and fail to achieve high affinity and low exchange rates for target metals.
Innovation Solution
Development of macrocyclic chelators with specific scaffold and chelating moieties that selectively bind thorium, utilizing oxygen donors for coordination, and incorporating targeting moieties for directed delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chelating agents are used for anticancer therapy, then they can bind metal ions, but they lack selectivity towards thorium and deplete essential biological metal ions
Solution Approach 1:
The patent applies local quality by designing chelating agents with specific functional groups (oxygen donors, carboxylates, phosphonates) positioned at particular locations within the macrocyclic structure. These localized chemical features create high affinity and selectivity for thorium ions while maintaining compatibility with biological systems, thereby achieving reliable thorium binding without depleting essential biological metal ions.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical composition, macrocyclic structure, and functional group characteristics of the chelating agents. By adjusting parameters such as ring size, substituent types, and coordination geometry, the invention optimizes selectivity for thorium while minimizing interference with biological metal ions, thus resolving the contradiction between reliability and harmful effects.
2Reliability
If current chelating agents are used, then they can chelate metal ions, but they fail to achieve high affinity and low exchange rates for target metals
Solution Approach 1:
The patent applies composite materials by combining multiple functional groups (carboxylates, phosphonates, oxygen donors) within a single macrocyclic chelating agent structure. This composite approach creates synergistic effects that enhance affinity for thorium ions and reduce exchange rates, thereby achieving high reliability and prolonged duration of action simultaneously. The multi-component design allows the chelator to form stable complexes with target metals while maintaining structural integrity for extended therapeutic use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The macrocyclic chelators demonstrate high selectivity and affinity for thorium, reducing the depletion of essential biological metal ions and enabling targeted therapeutic and diagnostic applications.
Implementation Method 1
selectively bind thorium, utilizing oxygen donors for coordination
Data Source
AI summary
The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.